Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 160

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 160
---
. On November 22, 2024, representatives of Jefferies commenced distributing drafts of the documentation for the PIPE Financing, including the forms of the Subscription Agreement, Registration
Rights Agreement and Pre-Funded Warrant, to prospective investors for review. Following such distribution, Aadi management and representatives of Wilson Sonsini directly negotiated the forms of such documents
with prospective investors and their counsel until the signing of the Subscription Agreement on December 19, 2024.

On November 19, 2024,
representatives of WuXi Biologics informed representatives of Aadi via telephone that splitting the upfront license fee payment into two payments might be acceptable depending on the amount of the payment due upon signing the License Agreement and
proposed at least $10.0 million for such payment.

On November 22, 2024, representatives of Aadi proposed via email to representatives of WuXi
Biologics certain revisions to the upfront license fee payment, including an $8.0 million upfront license fee payment due upon signing the License Agreement, $4.0 million of which would be refundable if Aadi failed to obtain stockholder
approval for the PIPE Financing. On the same day, representatives of WuXi Biologics proposed via email to representatives of Aadi certain counterproposals related to the upfront license fee payment, principally that the total amount of the upfront
license fee payment would be increased from $42.0 million to $44.0 million and the portion of the upfront license fee payment due upon signing the License Agreement would be increased from $4.0 million to $6.0 million and would
be entirely non-refundable. On November 24, 2024, representatives of Aadi communicated to representatives of WuXi Biologics that the proposed revisions were acceptable.

On November 26, 2024, representatives of WuXi Biologics shared with representatives of Aadi a revised draft of the License Agreement. Among other things,
as previously discussed between the parties, the revised draft of the License Agreement: (i) removed the concept of any portion of the upfront license fee payment or the effectiveness of the License Agreement being conditioned upon stockholder
approval of the PIPE Financing; (ii) provided that the total amount of the upfront license fee payment would be increased from $42.0 million to $44.0 million, $6.0 million of which would be payable within seven days of the
signing of the License Agreement (and would be non-refundable), and the